View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: November 23, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Aclaris Therapeutics Announces $80 Million Private Placement

Aclaris Therapeutics Announces $80 Million Private Placement WAYNE, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS) (the “Company” or “Aclaris”), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that it has entered into a securities purchase agreement with a group of accredited investors for the private placement of 35,555,555 shares of common stock at a purchase price of $2.25 per share, for gross proceeds of approximately $80.0 million. The private placement is expect...

 PRESS RELEASE

Aclaris Therapeutics Announces Exclusive, Global License Agreement wit...

Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline - Enhances Aclaris’ pipeline with complementary biologics portfolio -- Expands leadership team with addition of seasoned biotech executives -- Management to host conference call today at 8:30 AM ET - WAYNE, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) --  Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that it has entered ...

 PRESS RELEASE

Aclaris Therapeutics Reports Third Quarter 2024 Financial Results and ...

Aclaris Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update – First Patient Dosed in ATI-2138 Phase 2a Trial in Atopic Dermatitis As Previously Announced;Top-line Data Anticipated in First Half of 2025 – WAYNE, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the third quarter of 2024 and provided a corporate update. "The third quarter of 2024 marked an imp...

 PRESS RELEASE

Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinica...

Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis WAYNE, Pa., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that the first patient has been dosed in Aclaris' Phase 2a clinical trial of ATI-2138, an investigational oral covalent inhibitor of interleukin-2-inducible T cell kin...

 PRESS RELEASE

Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthca...

Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference WAYNE, Pa., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that members of the Aclaris management team will participate in a fireside chat during the 2024 Cantor Global Healthcare Conference on Tuesday, September 17, 2024 at 8:00 AM ET in New York, New York. A webcast of the fireside chat may be accessed through the “Events” page of the “In...

 PRESS RELEASE

Aclaris Therapeutics Reports Second Quarter 2024 Financial Results and...

Aclaris Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update -Initiated Phase 2a Study Activities for ATI-2138 in Atopic Dermatitis--Strengthened Balance Sheet Through Sale of Future OLUMIANT® Royalties for Proceeds of up to $31.5 Million- WAYNE, Pa., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the second quarter of 2024 and provided a corporate update. "Wi...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: August 3, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: July 31, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: July 27, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: July 22, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Aclaris Therapeutics Announces Sale of OLUMIANT® Royalties and Milesto...

Aclaris Therapeutics Announces Sale of OLUMIANT® Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million - Non-Dilutive Transaction Strengthens Balance Sheet to Support Strategic Priorities -- $26.5 Million Upfront Plus Up to $5.0 Million Milestone - WAYNE, Pa., July 16, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced the sale of a portion of Aclaris’ future royalty payments and certain milestones from Eli Lilly and C...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: July 13, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

DHIL DIAMOND HILL INVESTMENT GROUP
SHEN SHENANDOAH TELECOMMUNICATIONS COMPANY
SAIC SCIENCE APPLICATIONS INTERNATIONAL CORP.
PSEC PROSPECT CAPITAL CORPORATION
PLAY DAVE & BUSTER'S ENTERTAINMENT INC.
NFBK NORTHFIELD BANCORP INC.
CVBF CVB FINANCIAL CORP.
CRMT AMERICA'S CAR-MART INC.
BEN FRANKLIN RESOURCES INC.
AMSWA AMERICAN SOFTWARE INC. CL A
ACRS ACLARIS THERAPEUTICS INC.
CLI MACK-CALI REALTY CORPORATION
NAD NUVEEN QUALITY MUNICIPAL INCOM
FRD FRIEDMAN INDUSTRIES INC.
XOM EXXON MOBIL CORPORATION
DMLP DORCHESTER MINERALS L.P.
NHF NEXPOINT CREDIT STRATEGIES FUN
CLIR CLEARSIGN TECHNOLOGIES CORP
LILA LIBERTY LATIN AMERICA A
PRPL PURPLE INNOVATION
VICR INC.
FXNC VICOR CORP.
REKR FIRST NATIONAL CORP. OF VIRGINIA
GOSS REKOR SYSTEMS
RZLT GOSSAMER BIO
ADV REZOLUTE
DMAC INC.
CSU ADVANTAGE SOLUTIONS INC (A)
TSHA DIAMEDICA THERAPEUTICS INC.
NUVB CAPITAL SENIOR LIVING
PFX TAYSHA GENE THERAPIES
AVTE NUVATION BIO INC (A)
AUID PHENIXFIN CORP
CLOV AEROVATE THERAPEUTICS
NSPR INC.
ACHR IPSIDY INC.
TPST CLOVER HEALTH INV CORP
ASLE INSPIREMD INC
BIGZ ARCHER AVIATION INC
DOUG MILLENDO THERAPEUTICS
LNKB INC.
RH AERSALE CORP
IRON BLACKROCK INNOVATION AND GROWTH TST
NE DOUGLAS ELLIMAN INC
ADCT LINKBANCORP INC
ASPI RESTORATION HARDWARE HOLDINGS INC
EP DISC MEDICINE INC
NUZE NOBLE CORP (NEW)
PEO ADC THERAPEUTICS SA
BNED ASP ISOTOPES INC
DMA EMPIRE PETROLEUM CORP
NRBO NUZEE INC.
ARDS PETROLEUM & RESOURCES CORPORATION
MXF BARNES & NOBLE EDUCATION INC.
DESTRA MULTI ALTERNATIVE FUND
NEUROBO PHARMACEUTICALS INC
ARIDIS PHARMACEUTICALS
INC.
THE MEXICO FUND
INC.
Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: July 6, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

DHIL DIAMOND HILL INVESTMENT GROUP
WIRE ENCORE WIRE CORPORATION
SHEN SHENANDOAH TELECOMMUNICATIONS COMPANY
SAIC SCIENCE APPLICATIONS INTERNATIONAL CORP.
PSEC PROSPECT CAPITAL CORPORATION
NFBK NORTHFIELD BANCORP INC.
MPAA MOTORCAR PARTS OF AMERICA INC.
EGBN EAGLE BANCORP INC.
CVBF CVB FINANCIAL CORP.
CRMT AMERICA'S CAR-MART INC.
BEN FRANKLIN RESOURCES INC.
AMSWA AMERICAN SOFTWARE INC. CL A
ACRS ACLARIS THERAPEUTICS INC.
CLOV CLOVER PAKISTAN LTD.
CLI MACK-CALI REALTY CORPORATION
NAD NUVEEN QUALITY MUNICIPAL INCOM
OPOF OLD POINT FINANCIAL CORP.
FRD FRIEDMAN INDUSTRIES INC.
XOM EXXON MOBIL CORPORATION
DMLP DORCHESTER MINERALS L.P.
NHF NEXPOINT CREDIT STRATEGIES FUN
CLIR CLEARSIGN TECHNOLOGIES CORP
CLF CLIFFS NATURAL RESOURCES INC.
LILA LIBERTY LATIN AMERICA A
PRPL PURPLE INNOVATION
VICR INC.
VPLM VICOR CORP.
GOSS VOIP PAL.COM INC.
ADV GOSSAMER BIO
DMAC ADVANTAGE SOLUTIONS INC (A)
GRNT DIAMEDICA THERAPEUTICS INC.
TSHA GRANIT SKOPKE
NUVB TAYSHA GENE THERAPIES
PFX NUVATION BIO INC (A)
AVTE PHENIXFIN CORP
AUID AEROVATE THERAPEUTICS
NSPR INC.
ACHR IPSIDY INC.
ASLE INSPIREMD INC
BIGZ ARCHER AVIATION INC
GLSI AERSALE CORP
LNKB BLACKROCK INNOVATION AND GROWTH TST
RH GREENWICH LIFESCIENCES INC
IRON LINKBANCORP INC
VFC RESTORATION HARDWARE HOLDINGS INC
AEI DISC MEDICINE INC
EP VF CORPORATION
PYYX ALSET INC.
GRUSF EMPIRE PETROLEUM CORP
PEO PYXUS INTERNATIONAL INC
DMA GROWN ROGUE INTERNATIONAL INC.
NRBO PETROLEUM & RESOURCES CORPORATION
ARDS DESTRA MULTI ALTERNATIVE FUND
MXF NEUROBO PHARMACEUTICALS INC
ARIDIS PHARMACEUTICALS
INC.
THE MEXICO FUND
INC.
Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: July 5, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: June 22, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch